Gemcitabine-Oxaliplatin, Lenvatinib & Toripalimab Show Promise in Cholangiocarcinoma

A promising combination therapy is showing significant benefits for patients facing a particularly aggressive form of liver cancer, intrahepatic cholangiocarcinoma (ICC). Early results from a phase 2/3 clinical trial suggest that adding the drugs toripalimab and lenvatinib to standard chemotherapy (GEMOX) before surgery—a neoadjuvant approach—can substantially improve event-free survival in high-risk ICC cases. Which means patients are living longer without the cancer returning or progressing after initial treatment.

Understanding Intrahepatic Cholangiocarcinoma

Intrahepatic cholangiocarcinoma is a cancer that forms in the bile ducts inside the liver. It’s a relatively rare but challenging cancer, often diagnosed at a late stage when treatment options are limited. The prognosis is generally poor, highlighting the urgent need for more effective therapies. ICC differs from other types of biliary cancers, which originate in the ducts outside the liver. According to the American Cancer Society, risk factors include primary sclerosing cholangitis, liver flukes, and cirrhosis.

The GOLP Regimen: A Three-Pronged Attack

The treatment strategy under investigation, often referred to as GOLP, combines three distinct agents: gemcitabine-oxaliplatin (GEMOX), lenvatinib, and toripalimab. GEMOX is a standard chemotherapy regimen for ICC. Lenvatinib is a tyrosine kinase inhibitor, a type of targeted therapy that blocks the growth of blood vessels that feed tumors. Toripalimab is an immunotherapy drug, specifically a PD-1 inhibitor, which helps the body’s immune system recognize and attack cancer cells.

The trial, as reported by Medscape Medical News, involved 30 patients with advanced ICC who received this combination therapy before surgery. Patients received gemcitabine and oxaliplatin in cycles, alongside toripalimab every three weeks and daily lenvatinib for a year. Researchers analyzed tumor samples to understand how the cancer responded to the treatment, looking at factors like PD-L1 expression and genetic mutations.

Key Findings: A High Response Rate and Promising Survival Data

The results, as of July 1, 2022, with a median follow-up of 23.5 months, are encouraging. The objective response rate (ORR) – the percentage of patients whose tumors shrank significantly – was 80%. Specifically, 23 patients experienced a partial response, and one achieved complete remission. The median overall survival (OS) was 22.5 months, progression-free survival (PFS) was 10.2 months, and duration of response (DoR) was 11.0 months. A high disease control rate (DCR) of 93.3% was also observed.

Interestingly, the study found that patients with DNA damage response (DDR)-related gene mutations appeared to benefit more from the treatment, showing a higher ORR. Similarly, patients with higher levels of PD-L1 expression on their tumor cells also showed a trend toward better response, though this wasn’t statistically significant.

Navigating Side Effects

As with many cancer treatments, GOLP is associated with side effects. More than half of the patients (56.7%) experienced grade 3 or higher adverse events, meaning they were more severe and required intervention. The most common side effects were neutropenia (low white blood cell count, increasing risk of infection) and leukocytopenia (low white blood cell count). These side effects were generally manageable, but underscore the importance of close monitoring during treatment.

What Does This Mean for Patients?

These findings suggest that neoadjuvant GOLP could become a valuable option for patients with high-risk ICC who are candidates for surgery. By shrinking the tumor before surgery and potentially eliminating microscopic disease, this approach may improve long-term outcomes. However, it’s crucial to remember that this is a relatively modest phase 2/3 trial. Larger, randomized controlled trials are needed to confirm these results and establish GOLP as a standard of care. A phase-III, multicenter, double-blinded, randomized study has already been approved by the National Medical Products Administration (NMPA) to further validate these findings (No. 2021LP01825), as noted in the published abstract.

The Role of Biomarkers and Personalized Medicine

The observation that patients with DDR gene mutations and high PD-L1 expression may respond better to GOLP highlights the potential for personalized medicine in ICC treatment. Identifying these biomarkers could help doctors select patients who are most likely to benefit from this therapy. Further research is needed to fully understand the role of these and other biomarkers in predicting treatment response.

Ongoing Research and Future Directions

Beyond the ongoing phase-III trial, researchers are also exploring other combinations of therapies for ICC. A clinical trial (NCT07304388), registered in December 2025, is investigating the combination of HAIC (hepatic arterial infusion chemotherapy) with systemic chemotherapy, lenvatinib, and toripalimab. This reflects a broader trend toward multimodal treatment approaches in ICC, aiming to target the cancer from multiple angles.

Trial Registration and Access to Information

For those interested in learning more about the initial trial, it is registered on ClinicalTrials.gov under the identifier NCT03951597. This provides access to detailed study information, including eligibility criteria and contact information for the research team.

The development of neoadjuvant GOLP represents a significant step forward in the fight against intrahepatic cholangiocarcinoma. While further research is necessary, these early results offer hope for improved outcomes for patients facing this challenging disease. Patients should discuss treatment options with their healthcare team to determine the best course of action based on their individual circumstances.